ReviewNanomedicine (London, England)2025
Cancer targeting carfilzomib nanomedicine: a comprehensive review of delivery vehicles and efficacy.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors.Molecular pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer therapy is an ever-changing landscape in constant demand of innovative approaches. Carfilzomib (CFZ) is a tetrapeptide epoxyketone covalent proteasome inhibitor currently approved for the treatment of refractory multiple myeloma. CFZ has a litany of anti-cancer biological effects lending itself to the treatment of a broad number of malignancies. Like many anti-cancer agents, CFZ is marred by severe offsite toxicities that limit applications of the drug. As a result, many nanomedicine approaches have been explored to improve the therapeutic index of CFZ-based treatments. Nanoparticle mediated delivery of CFZ has emerged as a leading candidate. CFZ can be encapsulated in a diverse array of nanomedical formulations including lipid-based, polymer, inorganic, and nanocrystalline vehicles. Each vehicle subtype has unique properties allowing for opportunities for enhanced delivery as well as multimodal therapy. In this review, we will categorize and summarize CFZ nanomedicine methods while demonstrating the potential of CFZ in the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.